BSESudarshan Pharma Industries Ltd· Chemicals & PetrochemicalsHighNeutral
Announced Tue, 1 Apr, 2025 · 12:10 IST

The Board of Directors of the Company at their meeting held on 31-03-2025 (1) rescinded its decision to appoint Mr. Manoj Lodha as Executive Director & Chief Financial Officer upon his ....

Cfo ResignedPromoter Family Board EntryManagement Changes View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
—Next day
—
prior close
₹30.00
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used——
Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.0
10m
+0.0
15m
+0.0
30m
+0.0
Sessions after the filingfrom the prior close
StockMarketvs market
Reaction day
———
Next day
———
2d
———
3d
———
4d
———
5d
———
1w
———
15d
———
1m
———
2m
———
3m
———
UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

On March 31, 2025, the Board cancelled its earlier plan to appoint Mr. Manoj Lodha as Executive Director & CFO after he withdrew his consent citing unforeseen circumstances. Separately, the Board accepted Mr. Sachin Mehta's request to withdraw his prior resignation as CFO, meaning he will continue as Joint Managing Director & CFO from April 1, 2025. Mr. Sachin Mehta is a relative (family member) of Mr. Hemal Mehta, the Chairman & Managing Director. The net result is that the company's board composition remains unchanged, with no new external CFO or Executive Director joining.

Likely market impact

Stability for shareholders as leadership stays the same, with a promoter-family member continuing to hold both the JMD and CFO roles. The failed external CFO appointment may raise minor governance questions, but the quick reversal avoided a leadership vacuum.